Literature DB >> 7862458

No point mutation but decreased expression of the p16/MTS1 tumor suppressor gene in nasopharyngeal carcinomas.

Y Sun1, A Hildesheim, A E Lanier, Y Cao, K T Yao, N Raab-Traub, C S Yang.   

Abstract

Nasopharyngeal carcinoma (NPC) is a malignancy which occurs at high incidence in southern China and southeast Asia. The molecular mechanism of this disease, however, is not well understood. Recently, a homozygous deletion and/or loss of heterozygosity on chromosome 9p21-22 was found in several primary NPCs (Huang et al., Cancer Res. 54: 4003-4006, 1994), suggesting that a potential tumor suppressor gene(s) residing in this region may play a role in nasopharyngeal carcinogenesis. Since p16/MTS1, a potential tumor suppressor gene, whose mutations/deletions are frequently found in variety of tumor cells, was mapped to chromosome 9p21, we investigated the possible involvement of this gene in the development of NPC by mutational and Northern blot analysis. SSCP-direct sequencing revealed no point mutations of the p16/MTS-1 gene in any of 42 primary NPC biopsies from three geographical regions nor in two NPC cell lines. We did, however, observe a codon 140ala-->thr polymorphism in the gene, which has been previously reported as a point mutation. Furthermore, Northern analysis revealed a decreased expression of the p16/MTS1 gene in two out of two NPC cell lines as compared with immortalized/nontransformed cell lines. These results suggest that down regulation rather than a point mutation of the p16/MTS1 gene may play a role in the genesis of NPC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7862458

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.

Authors:  A K El-Naggar; S Lai; G Clayman; J K Lee; M A Luna; H Goepfert; J G Batsakis
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

2.  Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product.

Authors:  M L Gulley; J M Nicholls; B G Schneider; M B Amin; J Y Ro; J Geradts
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

3.  Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3.

Authors:  Y Cheng; N E Poulos; M L Lung; G Hampton; B Ou; M I Lerman; E J Stanbridge
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

4.  Chromosome 3p loss of heterozygosity and mutation analysis of the FHIT and beta-cat genes in squamous cell carcinoma of the head and neck.

Authors:  M V González; M F Pello; P Ablanedo; C Suárez; V Alvarez; E Coto
Journal:  J Clin Pathol       Date:  1998-07       Impact factor: 3.411

5.  STGC3 inhibits xenograft tumor growth of nasopharyngeal carcinoma cells by altering the expression of proteins associated with apoptosis.

Authors:  Qing-Chao Qiu; Bo Hu; Xiu-Pei He; Qiao Luo; Guo-Hua Tang; Zhi-Feng Long; Zhu-Chu Chen; Xiu-Sheng He
Journal:  Genet Mol Biol       Date:  2012-02-02       Impact factor: 1.771

6.  High prevalence of p16 genetic alterations in head and neck tumours.

Authors:  E C Miracca; L P Kowalski; M A Nagai
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

7.  Elevated expression of thyroid hormone receptor alpha 2 (c-erb A- alpha 2) in nasopharyngeal carcinoma.

Authors:  J W Lee; C L Chen; B T Juang; J Y Chen; C S Yang; S L Doong
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

8.  Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5.

Authors:  Naoko Ohtani; Paul Brennan; Stefan Gaubatz; Elaine Sanij; Paul Hertzog; Ernst Wolvetang; Jacques Ghysdael; Martin Rowe; Eiji Hara
Journal:  J Cell Biol       Date:  2003-07-14       Impact factor: 10.539

9.  Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas.

Authors:  G M Maelandsmo; V A Flørenes; E Hovig; T Oyjord; O Engebraaten; R Holm; A L Børresen; O Fodstad
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.